ETRA · Electra Therapeutics, Inc.
AI read · Good for ETRA
The AI's read
The IPO supports work on several drug programs, and Electra's lead drug is in a global study for a serious immune disorder. In an early study, all 12 patients were alive after 8 weeks, and all had responded by week 4. That is encouraging, but the group was small. Enrollment in the larger study is expected to finish in the second half of 2027, so important results are still ahead.